Table 1.
Patient characteristics
| TAC + ZA N = 122 (49.6%) |
TAC N = 124 (50.4%) |
IGF-1R biopsy data available N = 188 (76.4%) |
Serum data available N = 37 (15%) |
|
|---|---|---|---|---|
| Median age (range), Years | 48.0 (29–67) | 49.0 (34–70) | 49 (29–70) | 49 (34–65) |
| Median BMI (range), kg/m2 | 26.1 (18.5–40.0) | 25.0 (18.3–42.0) | 25.0 (18.3–42.0) | 24.9 (19.4–39.5) |
| Menopausal status | ||||
| Pre/peri | 72 (59.0%) | 75 (60.5%) | 110 (58.5%) | 24 (64.9%) |
| Post | 50 (41.0%) | 47 (37.9%) | 76 (40.4%) | 13 (35.1%) |
| T-classification | ||||
| T1/T2 | 73 (59.8%) | 71 (57.3%) | 108 (57.4%) | 21 (56.8%) |
| T3/T4 | 49 (40.2%) | 53 (42.7%) | 80 (42.6%) | 16 (43.2%) |
| N-classification | ||||
| N0 | 54 (44.3%) | 56 (45.2%) | 90 (47.9%) | 22 (59.5%) |
| N+ | 68 (55.7%) | 68 (54.8%) | 98 (52.1%) | 15 (40.5%) |
| HR-status | ||||
| ER+ and/or PR+ | 101 (82.8%) | 104 (83.9%) | 158 (84.0%) | 33 (89.2%) |
| ER− and PR− | 21 (17.2%) | 20 (16.1%) | 30 (16.0%) | 4 (10.8%) |
TAC docetaxel, doxorubicin and cyclophosphamide, ZA zoledronic acid, BMI body mass index, HR hormone receptor, ER estrogen receptor, PR progesterone receptor, pCR pathologic complete response, LN lymph nodes, MP Miller and Payne